Difference between revisions of "Sunitinib (Sutent)"
Jump to navigation
Jump to search
(updated content) |
|||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Tyrosine kinase inhibitor, inhibits multiple tyrosine kinases, including: vascular endothelial growth factor receptor (VEGFR1, VEGFR2 and VEGFR3), platelet-derived growth factor receptors (PDGFRα and PDGFRβ), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and RET. Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=607 Sunitinib (Sutent) package insert]</ref><ref>[ | + | Class/mechanism: Tyrosine kinase inhibitor, inhibits multiple tyrosine kinases, including: vascular endothelial growth factor receptor (VEGFR1, VEGFR2 and VEGFR3), platelet-derived growth factor receptors (PDGFRα and PDGFRβ), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and RET. Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=607 Sunitinib (Sutent) package insert]</ref><ref>[[Media:Sunitinib.pdf | Sunitinib (Sutent) package insert (locally hosted backup)]]</ref><ref>[http://sutent.com/ Sutent manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 17: | Line 15: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://labeling.pfizer.com/ShowLabeling.aspx?id=607 | + | *[http://labeling.pfizer.com/ShowLabeling.aspx?id=607 Sunitinib (Sutent) package insert]<ref name="insert"></ref> |
| − | *[http://chemocare.com/ | + | *[http://www.chemocare.com/chemotherapy/drug-info/Sunitinib.aspx Sunitinib (Sutent) patient drug information (Chemocare)]<ref>[http://www.chemocare.com/chemotherapy/drug-info/Sunitinib.aspx Sunitinib (Sutent) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/sunitinib-patient-drug-information Sunitinib (Sutent) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/sunitinib-patient-drug-information Sunitinib (Sutent) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/sunitinib-patient-drug-information Sunitinib (Sutent) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/sunitinib-patient-drug-information Sunitinib (Sutent) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 1/26/2006: Initial FDA approval: | + | * 1/26/2006: [http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021968lbl.pdf Initial FDA approval]: |
# "for the treatment of [[Sarcoma | gastrointestinal stromal tumor]] after disease progression on or intolerance to [[Imatinib (Gleevec) | imatinib mesylate]]." | # "for the treatment of [[Sarcoma | gastrointestinal stromal tumor]] after disease progression on or intolerance to [[Imatinib (Gleevec) | imatinib mesylate]]." | ||
# "for the treatment of advanced [[Renal cancer | renal cell carcinoma]]." | # "for the treatment of advanced [[Renal cancer | renal cell carcinoma]]." | ||
| + | *5/20/2011: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm256499.htm FDA approved] for treatment of "Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease." | ||
| + | |||
| + | ==Also known as== | ||
| + | SU11248. | ||
==References== | ==References== | ||
Revision as of 05:02, 17 November 2014
General information
Class/mechanism: Tyrosine kinase inhibitor, inhibits multiple tyrosine kinases, including: vascular endothelial growth factor receptor (VEGFR1, VEGFR2 and VEGFR3), platelet-derived growth factor receptors (PDGFRα and PDGFRβ), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and RET. Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Hepatobiliary cancer
- Pancreatic neuroendocrine islet cell tumors
- Renal cancer
- Sarcoma
- Testicular cancer
- Thyroid cancer
Patient drug information
- Sunitinib (Sutent) package insert[1]
- Sunitinib (Sutent) patient drug information (Chemocare)[4]
- Sunitinib (Sutent) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1/26/2006: Initial FDA approval:
- "for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate."
- "for the treatment of advanced renal cell carcinoma."
- 5/20/2011: FDA approved for treatment of "Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease."
Also known as
SU11248.
References
Categories:
- Drug index
- Chemotherapy
- Oral chemotherapy
- Kinase inhibitors
- FLT3 inhibitors
- KIT inhibitors
- PDGFR inhibitors
- RET inhibitors
- VEGF inhibitors
- Hepatobiliary cancer medications
- Neuroendocrine tumor medications
- Renal cancer medications
- Sarcoma medications
- Testicular cancer medications
- Thyroid cancer medications
- Drugs FDA approved in 2006